Sastasundar Ven. (SASTASUNDR)

FairStock Score: 31/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Debt/Equity of 0.01 indicates a very strong balance sheet with low financial risk.
• Promoter holding of 74.69% shows strong ownership alignment.
• Sales growth of 22.91% shows the business is expanding its top line.
• Piotroski F-Score of 6/9 suggests moderate fundamental health and operational improvement.

Concerns

• Latest quarter Net Profit is ₹0 Cr, with ROE -0.32% and ROCE -1.33%, meaning no real profitability.
• P/E of 34.74 is expensive for a company earning almost nothing; P/B of 3.22 is a steep premium to book value of ₹83.73.
• Profit growth of 104.35% is misleading because it comes from a very low base.
• No dividend yield and FairStock Score of 29/100 indicate a risky investment.

AI Analysis

Let me analyse Sastasundar Ven. the way I would any business. Healthcare services is a decent industry—people will always need medical care—but a good industry doesn't automatically make a good investment. The operating record here is weak. ROE is -0.32% and ROCE is -1.33%, so the company is not yet earning an acceptable return on the capital shareholders have put in. The latest quarter shows net profit of roughly ₹0 Cr. That is the critical fact. A business earning nothing cannot support a P/E of 34.74 at ₹269.25. I am being asked to pay about 3.22 times book value of ₹83.73 for a company that has yet to prove its profitability. That leaves little margin of safety. There are some positives. Debt-to-equity is only 0.01, so the company is not hostage to lenders. Promoter holding at 74.69% tells me owners have skin in the game. Sales grew 22.91%, and profit growth of 104.35% is reported—but when starting from a small loss, such percentages can be deceptive. The Piotroski score of 6/9 suggests some improvement in operations, but not enough for me to abandon my standards. With no dividend yield, I get no income while waiting. The PEG ratio of 0.55 looks cheap, but with net profit at ₹0 Cr, the E in the denominator is unreliable. FairStock Score of 29/100 flags risk, and the 52-week range of ₹252.50 to ₹363.00 shows the price has already fallen sharply. This is not a wonderful business at a fair price; it is a possible turnaround selling at a price that assumes a future I cannot verify. I would watch it, but I would not buy it today.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer